228
Views
9
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLESClinical Translational Therapeutics

PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance

, , , , , , , , , & show all
Pages 1044-1051 | Published online: 11 Jun 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Niki Karachaliou, Maria de los Llanos Gil Moreno, Aaron E. Sosa, Mariacarmela Santarpia, Chiara Lazzari, Alejandra Rodriguez Capote, Bartomeu Massuti & Rafael Rosell. (2017) Using genetics to predict patient response to platinum-based chemotherapy. Expert Review of Precision Medicine and Drug Development 2:1, pages 21-32.
Read now

Articles from other publishers (8)

Nikolaos Nikoleousakos, Panagiotis Dalezis, Aikaterini Polonifi, Elena G. Geromichalou, Sofia Sagredou, Constantinos E. Alifieris, Maria V. Deligiorgi, Vasiliki Sarli & Dimitrios T. Trafalis. (2021) Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay. Biomedicines 9:8, pages 1028.
Crossref
Luca Campedel, Paul Blanc-Durand, Asker Bin Asker, Jacqueline Lehmann-Che, Caroline Cuvier, Cedric De Bazelaire, Luis Teixeira, Stephanie Becourt, Florence Ledoux, Hamid Hocini, Edwige Bourstyn, Catherine Miquel, Sophie Guillerm, Patrick Charveriat, Marc Espié, Anne De Roquancourt, Anne-Sophie Hamy & Sylvie Giacchetti. (2020) Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC. Cancers 12:9, pages 2657.
Crossref
Vaishali Jayashankar & Aimee L. Edinger. (2020) Macropinocytosis confers resistance to therapies targeting cancer anabolism. Nature Communications 11:1.
Crossref
Claudia Gasch, Brendan Ffrench, John J. O’Leary & Michael F. Gallagher. (2017) Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Molecular Cancer 16:1.
Crossref
Brendan Ffrench, Claudia Gasch, Karsten Hokamp, Cathy Spillane, Gordon Blackshields, Thamir Mahmoud Mahgoub, Mark Bates, Louise Kehoe, Aoibhinn Mooney, Ronan Doyle, Brendan Doyle, Dearbhaile O'Donnell, Noreen Gleeson, Bryan T Hennessy, Britta Stordal, Ciaran O'Riain, Helen Lambkin, Sharon O'Toole, John J O'Leary & Michael F Gallagher. (2017) CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy. Cell Death & Disease 8:10, pages e3128-e3128.
Crossref
Bo Pang, Shi Cheng, Shi-Peng Sun, Cheng An, Zhi-Yuan Liu, Xue Feng & Gui-Jian Liu. (2014) Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Scientific Reports 4:1.
Crossref
Jacqueline Lehmann-Che, Anne-Sophie Hamy, Raphaël Porcher, Marc Barritault, Fatiha Bouhidel, Hanadi Habuellelah, Solenne Leman-Detours, Anne de Roquancourt, Laurence Cahen-Doidy, Edwige Bourstyn, Patricia de Cremoux, Cedric de Bazelaire, Marcela Albiter, Sylvie Giacchetti, Caroline Cuvier, Anne Janin, Marc Espié, Hugues de Thé & Philippe Bertheau. (2013) Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Research 15:3.
Crossref
C.B. Murat, P.B.S. Braga, M.A.H.Z. Fortes, M.D. Bronstein, M.L.C. Corrêa-Giannella & R.R. Giorgi. (2012) Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. Brazilian Journal of Medical and Biological Research 45:9, pages 851-855.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.